Heather Bresch is CEO of Mylan, one of the world’s leading pharmaceutical companies. She also serves on the company’s board of directors. Throughout her 25-year career with Mylan, Bresch has held roles of increasing responsibility in more than 15 functional areas, and played a key leadership role in a series of large, transformative acquisitions, which more than doubled Mylan’s size. She now is leading Mylan in its next chapter of sustainable growth, which is expected to again significantly expand the size and scope of the company. In achieving Mylan’s goals, Bresch is aligning employees behind Mylan’s mission to deliver high quality medicine to the world’s 7 billion people and create better health for a better world. She emphasizes a collaborative culture focused on leading, learning, teaching and performing. Bresch also is a leader on key industry issues and policy initiatives aimed at removing barriers to access to medicine. Among her policy priorities, Bresch has been a leading advocate for global competitiveness and global quality standards. For instance, driven by Mylan’s unmatched commitment to quality, Bresch was instrumental in the development of the Generic Drug User Fee Act (GDUFA) which aims to hold all drugs sold in the U.S. to one quality standard. Bresch was elected to serve as chair of the Generic Pharmaceutical Association’s board of directors in 2016. Previously, she served two one-year terms as the chair of the association in 2004 and 2005 and two one-year terms as vice chair in 2003 and 2006.

Share this
Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInPin on PinterestBuffer this pageEmail this to someone